Cell MedX Corp (CMXC)
Stock Price:
$0.423 USD
-0.027 (-6.00%)
Updated Oct 16, 2020 12:47 PM EDT - Market closed
Key Info
| Market Cap |
25.12M |
| Revenue (ttm) |
76,990 |
| Net Income (ttm) |
-1.05M |
| Shares Out |
59.39M |
| EPS (ttm) |
-0.02 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 16, 2020 |
| Last Price |
$0.423 |
| Previous Close |
$0.450 |
| Change ($) |
-0.027 |
| Change (%) |
-6.00% |
| Day's Open |
0.464 |
| Day's Range |
0.400 - 0.464 |
| Day's Volume |
43,929 |
| 52-Week Range |
0.1645 - 0.7 |
More Stats
| Market Cap |
25.12M |
| Enterprise Value |
25.59M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
59.39M |
| Float |
26.95M |
| EPS (basic) |
-0.02 |
| EPS (diluted) |
-0.02 |
| FCF / Share |
-0.02 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.13 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
326.29 |
| PB Ratio |
n/a |
| Revenue |
76,990 |
| Operating Income |
-994,772 |
| Net Income |
-1.05M |
| Free Cash Flow |
-893,365 |
| Net Cash |
-471,421 |
| Net Cash / Share |
-0.01 |
| Gross Margin |
111.17% |
| Operating Margin |
-1,292.08% |
| Profit Margin |
-1,362.00% |
| FCF Margin |
-1,160.36% |
| ROA |
-180.50% |
| ROE |
n/a |
| ROIC |
-174.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 0.10 | - | - | 0.01 | 0.04 | 0.04 | - | - | - | - |
| Revenue Growth | - | - | - | -82.99% | -14.23% | - | - | - | - | - |
| Gross Profit | 0.09 | - | - | - | 0.01 | 0.02 | - | - | - | - |
| Operating Income | -1.04 | -0.67 | -1.54 | -1.22 | -2.10 | -0.94 | -0.02 | -0.01 | -0.02 | -0.01 |
| Net Income | -1.09 | -0.91 | -1.55 | -1.25 | -2.14 | -1.03 | -0.02 | -0.01 | -0.02 | -0.01 |
| Shares Outstanding | 53.48 | 44.28 | 42.31 | 36.86 | 31.00 | 31.00 | 31.00 | 31.00 | 30.27 | 30.00 |
| Earnings Per Share | -0.02 | -0.02 | -0.04 | -0.03 | -0.07 | -0.03 | - | - | - | - |
| Operating Cash Flow | -0.93 | -0.31 | -0.45 | -0.75 | -0.42 | -0.32 | -0.01 | -0.01 | -0.02 | -0.02 |
| Capital Expenditures | - | - | - | -0.11 | -0.22 | -0.03 | - | - | - | - |
| Free Cash Flow | -0.93 | -0.31 | -0.45 | -0.86 | -0.64 | -0.34 | -0.01 | -0.01 | -0.02 | -0.02 |
| Cash & Equivalents | 0.05 | 0.06 | 0.01 | 0.07 | 0.03 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 |
| Total Debt | 0.50 | 0.51 | 0.12 | 0.54 | 0.95 | 0.27 | - | - | - | - |
| Net Cash / Debt | -0.46 | -0.45 | -0.11 | -0.47 | -0.92 | -0.27 | 0.00 | 0.01 | 0.02 | 0.00 |
| Assets | 0.16 | 0.19 | 0.05 | 0.29 | 0.27 | 0.05 | - | 0.01 | 0.02 | - |
| Liabilities | 1.68 | 1.96 | 1.12 | 1.46 | 1.68 | 0.73 | 0.02 | 0.01 | 0.01 | - |
| Book Value | -1.52 | -1.77 | -1.07 | -1.17 | -1.41 | -0.68 | -0.02 | - | 0.01 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cell MedX Corp |
| Country |
United States |
| CEO |
Frank E. Mcenulty |
Stock Information
| Ticker Symbol |
CMXC |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
OTCMKTS: CMXC |
Description
Cell MedX, a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general relaxation and for the temporary relief of pain due to sore and/or aching muscles. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada.